TCM Prescription: Le Ma Hui Tablets



Prescription Description
Prescription IDTCMFx4821
Pinyin NameLe Ma Hui Pian
Chinese Name勒马回片
English NameLe Ma Hui Tablets
Function Description咳血, 咳嗽, 热淋
IndicationsHeat stranguria disorder, Hemoptysis, Acute prostatitis, Chronic prostatitis, Salmonella pyelonephritis, Chronic pyelonephritis, Cystitis, Urethritis
Disease ICD-11 Category SA91 [Heat stranguria disorder (TM1), 热淋 (TM1) ];
MD22 [Haemoptysis, 咯血 ];
GA91.Y [Other specified inflammatory and other diseases of prostate, 其他特指的前列腺炎性疾病 ];
GA91.0 [Chronic prostatitis, 慢性前列腺炎 ];
GC2Z [Diseases of the urinary system, unspecified, 泌尿系统疾病,未特指的 ];
GB55.Z [Chronic tubulo-interstitial nephritis, unspecified, 慢性肾小管-间质肾炎,未特指的 ];
GC00 [Cystitis, 膀胱炎 ];
GC02.Y [Other specified urethritis and urethral syndrome, 其他特指的尿道炎和尿道综合征 ];
Human Tissues Associated with IndicationLung
ReferenceCFDA
Reference Book/linkhttp://samr.cfda.gov.cn/WS01/CL0001/
Prescription Components
Component ID Latin Name Chinese Name Component Quantity Barcode
TCMH1996 Veronica linariifolia sp. dilatata 水蔓菁 TCMH1996
Reference: CFDA

Targeted Human Proteins by the Ingredients of Prescription

Target ID Gene Symbol Target Name Target Class Uniprot ID


Targeted Pathogenic Microbes by the Ingredients of Prescription

Target ID Target Name

Gene Ontology Associated to Targeted Human Proteins

GO Term GO Name Enriched Genes Log10 Adjusted P-value


KEGG Pathways Associated to Targeted Human Proteins

KEGG Pathway ID Enriched Genes Log10 Adjusted P-value


Target Exprsssion in Healthy Human Tissues (protein & mRNA level)

Protein expression data was from the "Human Proteome Map" dataset
mRNA expression data was from the "GTEx" dataset



Average Target Expression (Fold Change) in Multiple Disease Conditions

Fold Change with Corresponding Normal Samples
Click each cell within the heatmap to access gene expression of individual patient samples
Data Section
Select to Download
1. General Information of Prescription  
2. Putative Targets  
3. Activity & References for Filtering Putative Targets  
4. GO & Pathway